Latest filings (excl ownership)
6-K
OKYO Pharma Announces Chairman Acquires Shares
10 Sep 24
6-K
OKYO Pharma Announces Chairman Acquires Shares
5 Sep 24
6-K
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
27 Aug 24
6-K
Current report (foreign)
23 Aug 24
6-K
OKYO Pharma Announces Chairman Acquires Shares
23 Aug 24
6-K
OKYO Pharma Announces Chairman Acquires Shares
21 Aug 24
6-K
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
15 Aug 24
20-F
2024 FY
Annual report (foreign)
13 Aug 24
6-K
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
6 Aug 24
NT 20-F
Notice of late annual filing (foreign)
31 Jul 24
6-K
Current report (foreign)
11 Jul 24
6-K
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
10 Jul 24
6-K
Current report (foreign)
10 Jul 24
6-K
OKYO Pharma Announces Participation in May 2024 Investor Conferences
8 May 24
6-K
Current report (foreign)
30 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
29 Mar 24
6-K
Current report (foreign)
22 Mar 24
6-K
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
21 Mar 24
6-K
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
20 Mar 24
6-K
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
9 Feb 24
6-K
Current report (foreign)
31 Jan 24
6-K
Current report (foreign)
8 Jan 24
6-K
Current report (foreign)
5 Jan 24
6-K
Current report (foreign)
21 Dec 23
424B5
Prospectus supplement for primary offering
20 Dec 23
6-K
Current report (foreign)
18 Dec 23
424B5
Prospectus supplement for primary offering
15 Dec 23
6-K
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
4 Dec 23
6-K
Current report (foreign)
29 Nov 23
6-K
Current report (foreign)
1 Nov 23
424B5
Prospectus supplement for primary offering
31 Oct 23
6-K
OKYO Pharma Announces $5.84 Million cash raise and payables reduction
31 Oct 23
6-K
Current report (foreign)
10 Oct 23
6-K
Current report (foreign)
5 Oct 23
6-K
Current report (foreign)
15 Sep 23
6-K
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
15 Sep 23
424B5
Prospectus supplement for primary offering
15 Sep 23
Latest ownership filings
4
GABRIELE M CERRONE
31 Oct 23
4
JOHN P BRANCACCIO
28 Sep 23
4
GABRIELE M CERRONE
20 May 22
4
GARY S JACOB
19 May 22
4
GABRIELE M CERRONE
19 May 22
4/A
GABRIELE M CERRONE
18 May 22
4
GABRIELE M CERRONE
18 May 22
3
Keeren Shah
16 May 22
3
Willy Jules Simon
16 May 22
3
JOHN P BRANCACCIO
16 May 22
3
GABRIELE M CERRONE
16 May 22
3
Bernard Denoyer
16 May 22
3
GARY S JACOB
16 May 22